# Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

> **NCT05831007** · NA · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **GENETIC:** LX102-C01 Injection

## Key facts

- **NCT ID:** NCT05831007
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-06
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831007, "Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05831007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*